SRR1797297
— · cohortMD1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortMD1
- subtype
- cohortMD1
- age_years
- 69
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1340907 | GTEX | — | 0.896 |
| 2 | SRR1311285 | GTEX | — | 0.892 |
| 3 | SRR1357434 | GTEX | — | 0.882 |
| 4 | SRR1367870 | GTEX | — | 0.878 |
| 5 | SRR650198 | — | — | 0.876 |
| 6 | SRR1319837 | GTEX | — | 0.875 |
| 7 | ERR2278876 | — | — | 0.874 |
| 8 | SRR1387199 | GTEX | — | 0.874 |
| 9 | aMVAC.P_005_TURBT_S223 | — | — | 0.874 |
| 10 | SRR1335651 | GTEX | — | 0.873 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 8 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.240 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.160 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.150 | Temsirolimus | — uncovered |
| SPERMATOGENESIS | 0.090 | Inavolisib | — uncovered |
| PEROXISOME | 0.070 | Idelalisib | — uncovered |
| MYOGENESIS | 0.040 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.030 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.010 | Inavolisib | — uncovered |